Thursday, May 23, 2024 7:44:37 AM
In addition to not adequately addressing the slowing of brain atrophy and how meaningful and stat. sig. blarcamesine’s results are in broad brain regions, after 48 weeks of treatment, p = .0005, she glosses over the efficacy results as if they are only slightly better than placebo. How laughable is that! It’s doubtful she’s that naïve… most likely an intended tactic to generate uncertainty. It’s rather curious that she didn’t include the actual stats for the ADAS-Cog and CDR-SB results… which are quite significant and far better than placebo or any MAB… and meets the new FDA requirements.
• Change from baseline to 48 weeks between the blarcamesine and placebo groups in least-squares mean (LSM) using mixed model for repeated measures (MMRM)1:
ADAS-Cog13: -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226)
CDR-SB: -0.456 [95% CI, -0.831 to -0.080]; (P = 0.0175)
• Validated biomarkers of amyloid beta pathology, plasma Aß 42/40 ratio increased significantly (P = 0.048)
• Significant reduction in brain volume loss, including whole brain (P = 0.0005), measured through MRI
• ANAVEX®2-73 (blarcamesine) was generally safe and well tolerated
She repeatedly and falsely states that blarcamesine is only slightly better than placebo. She either doesn’t know or conveniently overlooks that blarcamesine has been proven to restore cellular homeostasis. A placebo cannot do that. Thus, when given early in disease progression (at first diagnosis or prophylactically), blarcamesine can restore/maintain cognition and daily living function. A placebo cannot do that. It’s why there’s a group of strong AD responders who IMPROVED over an identified threshold… >3x more than placebo, for both cognition and function.
She also fails to mention that, after initial review of the AD data, the EMA encouraged (“pulled”) Anavex to submit an MAA filing… which they are working diligently to submit as soon as possible this year. This, undoubtedly, will lead to approval.
These are details that she “conveniently” omits from her soft-bash article.
She recommends a “hold” because a “sell” recommendation would be most ridiculous… and her handlers certainly don’t want anyone buying, because that’s for them and institutions to do.
Remember… they have 20M collusive short positions to cover… thus, the soft-bash hit piece.
The reality is (and WS knows) that blarcamesine will be approved, as significantly effective and safe for a host of CNS disorders. It’s why the price has been severely manipulated down behind a chorus of paid FUDsters posting bullschitt 24x7 on this board, as well as other social media platforms. It’s all one big, coordinated pool of corruption and lies.
Okay… now cue BioCrapper4 and the other FUDsters to defend their tribe.
Recent AVXL News
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM